{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:32:52Z","timestamp":1775244772334,"version":"3.50.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Breast cancer is the most common cancer among women worldwide and the second leading cause of brain metastases (BrM). We assessed the treatment patterns and outcomes of women treated for breast cancer BrM at our institution in the modern era of stereotactic radiosurgery (SRS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective analysis of women (\u226518\u2009years of age) with metastatic breast cancer who were treated with surgery, whole brain radiotherapy (WBRT), or SRS to the brain at the Sunnybrook Odette Cancer Centre, Toronto, Canada, between 2008 and 2018. Patients with a history of other malignancies and those with an uncertain date of diagnosis of BrM were excluded. Descriptive statistics were generated and survival analyses were performed with subgroup analyses by breast cancer subtype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 683 eligible patients, 153 (22.4%) had triple-negative breast cancer, 188 (27.5%) had HER2+, 246 (36.0%) had hormone receptor (HR)+\/HER2\u2212, and 61 (13.3%) had breast cancer of an unknown subtype. The majority of patients received first-line WBRT (n =\u2009459, 67.2%) or SRS (n =\u2009126, 18.4%). The median brain-specific progression-free survival and median overall survival (OS) were 4.1 months (interquartile range [IQR] 1.0\u20139.6 months) and 5.1 months (IQR 2.0\u201311.7 months) in the overall patent population, respectively. Age &amp;gt;60\u2009years, presence of neurological symptoms at BrM diagnosis, first-line WBRT, and HER2\u2212 subtype were independently prognostic for shorter OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite the use of SRS, outcomes among patients with breast cancer BrM remain poor. Strategies for early detection of BrM and central nervous system\u2013active systemic therapies warrant further investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Although triple-negative breast cancer and HER2+ breast cancer have a predilection for metastasis to the central nervous system (CNS), patients with hormone receptor\u2013positive\/HER2\u2212 breast cancer represent a high proportion of patients with breast cancer brain metastases (BrM). Hence, clinical trials should include patients with BrM and evaluate CNS-specific activity of novel systemic therapies when feasible, irrespective of breast cancer subtype. In addition, given that symptomatic BrM are associated with shorter survival, this study suggests that screening programs for the early detection and treatment of breast cancer BrM warrant further investigation in an era of minimally toxic stereotactic radiosurgery.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13965","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T17:46:34Z","timestamp":1631295994000},"page":"e1951-e1961","source":"Crossref","is-referenced-by-count":19,"title":["Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A <scp>Single-Center<\/scp> Retrospective Study"],"prefix":"10.1093","volume":"26","author":[{"given":"Yizhuo Kelly","family":"Gao","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Kuksis","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badr","family":"Id Said","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Chehade","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Kiss","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Sickandar","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Warner","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-0308","authenticated-orcid":false,"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada"},{"name":"Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"2022011714461606900_onco13965-bib-0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2022011714461606900_onco13965-bib-0002","volume-title":"Surveillance, Epidemiology, and End Results Program","author":"National Institutes of Health"},{"key":"2022011714461606900_onco13965-bib-0003","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022011714461606900_onco13965-bib-0004","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022011714461606900_onco13965-bib-0005","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"key":"2022011714461606900_onco13965-bib-0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10552-011-9859-8","article-title":"Factors associated with mortality after breast cancer metastasis","volume":"23","author":"Jung","year":"2012","journal-title":"Cancer Causes Control"},{"key":"2022011714461606900_onco13965-bib-0007","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1524-4741.2012.01246.x","article-title":"Limited overall survival in patients with brain metastases from triple negative breast cancer","volume":"18","author":"Morris","year":"2012","journal-title":"Breast J"},{"key":"2022011714461606900_onco13965-bib-0008","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10549-007-9806-2","article-title":"Brain metastases in breast cancer: Prognostic factors and management","volume":"111","author":"Lee","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2022011714461606900_onco13965-bib-0009","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-007-9469-1","article-title":"Treatment and prognosis of brain metastases from breast cancer","volume":"86","author":"Ogawa","year":"2008","journal-title":"J Neurooncol"},{"key":"2022011714461606900_onco13965-bib-0010","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: Summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022011714461606900_onco13965-bib-0011","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.ijrobp.2011.02.027","article-title":"Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases","volume":"82","author":"Sperduto","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022011714461606900_onco13965-bib-0012","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/cam4.439","article-title":"Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy","volume":"4","author":"Leone","year":"2015","journal-title":"Cancer Med"},{"key":"2022011714461606900_onco13965-bib-0013","first-page":"21","article-title":"Management of brain metastases from breast carcinoma","volume":"7","author":"Flowers","year":"1993","journal-title":"Oncology (Williston Park)"},{"key":"2022011714461606900_onco13965-bib-0014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1006486423827","article-title":"Radiation therapy in the management of brain metastases from breast cancer","volume":"62","author":"Fokstuen","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"2022011714461606900_onco13965-bib-0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s00066-004-1299-x","article-title":"Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery","volume":"180","author":"Combs","year":"2004","journal-title":"Strahlenther Onkol"},{"key":"2022011714461606900_onco13965-bib-0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1023\/A:1006490200335","article-title":"Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma","volume":"65","author":"Lederman","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"2022011714461606900_onco13965-bib-0017","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3171\/2013.4.JNS121751","article-title":"Survival among patients with 10 or more brain metastases treated with stereotactic radiosurgery","volume":"119","author":"Rava","year":"2013","journal-title":"J Neurosurg"},{"key":"2022011714461606900_onco13965-bib-0018","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3171\/2013.2.JNS121213","article-title":"Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain: Clinical article","volume":"118","author":"Salvetti","year":"2013","journal-title":"J Neurosurg"},{"key":"2022011714461606900_onco13965-bib-0019","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ijrobp.2014.10.024","article-title":"Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: Individual patient data meta-analysis","volume":"91","author":"Sahgal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022011714461606900_onco13965-bib-0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(14)71106-4","article-title":"Stereotactic radiosurgery alone for brain metastases","volume":"16","author":"Sahgal","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022011714461606900_onco13965-bib-0021","first-page":"923","article-title":"Multidisciplinary management of breast cancer brain metastases","volume":"30","author":"Zagar","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"2022011714461606900_onco13965-bib-0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-015-2009-5","article-title":"Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: A prospective trial","volume":"127","author":"Pham","year":"2016","journal-title":"J Neurooncol"},{"key":"2022011714461606900_onco13965-bib-0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijrobp.2017.04.037","article-title":"A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 Study Update): Irradiation-related complications and long-term maintenance of mini-mental state examination scores","volume":"99","author":"Yamamoto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022011714461606900_onco13965-bib-0024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","article-title":"Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial","volume":"22","author":"Meyers","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022011714461606900_onco13965-bib-0025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/030089160909500610","article-title":"Brain metastases secondary to breast cancer: Symptoms, prognosis and evolution","volume":"95","author":"Oltean","year":"2009","journal-title":"Tumori"},{"key":"2022011714461606900_onco13965-bib-0026","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2002.07.500","article-title":"Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points","volume":"20","author":"Mehta","year":"2002","journal-title":"J Clin Oncol"},{"key":"2022011714461606900_onco13965-bib-0027","first-page":"214","article-title":"Quality of reporting and assessment of patient-reported health-related quality of life in patients with brain metastases: A systematic review","volume":"5","author":"DiRisio","year":"2018","journal-title":"Neurooncol Pract"},{"key":"2022011714461606900_onco13965-bib-0028","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ijrobp.2007.03.048","article-title":"Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone","volume":"68","author":"Aoyama","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022011714461606900_onco13965-bib-0029","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12885-020-6559-3","article-title":"The neurocognitive function change criteria after whole-brain radiation therapy for brain metastasis, in reference to health-related quality of life changes: A prospective observation study","volume":"20","author":"Nakano","year":"2020","journal-title":"BMC Cancer"},{"key":"2022011714461606900_onco13965-bib-0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-811161-1.00006-2","article-title":"Brain metastasis: Clinical manifestations, symptom management, and palliative care","volume":"149","author":"Noh","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"2022011714461606900_onco13965-bib-0031","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-014-1543-x","article-title":"Cognition in patients with newly diagnosed brain metastasis: Profiles and implications","volume":"120","author":"Gerstenecker","year":"2014","journal-title":"J Neurooncol"},{"key":"2022011714461606900_onco13965-bib-0032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-811161-1.00012-8","article-title":"Neurocognitive aspects of brain metastasis","volume":"149","author":"Wefel","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"2022011714461606900_onco13965-bib-0033","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022011714461606900_onco13965-bib-0034","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2019.11.001","article-title":"Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort","volume":"125","author":"Pasquier","year":"2020","journal-title":"Eur J Cancer"},{"key":"2022011714461606900_onco13965-bib-0035","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"2022011714461606900_onco13965-bib-0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.07.004","article-title":"Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry","volume":"102","author":"Witzel","year":"2018","journal-title":"Eur J Cancer"},{"key":"2022011714461606900_onco13965-bib-0037","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","article-title":"Brain metastases in newly diagnosed breast cancer: A population-based study","volume":"3","author":"Martin","year":"2017","journal-title":"JAMA Oncol"},{"key":"2022011714461606900_onco13965-bib-0038","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-18-2366","article-title":"Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: Patient characteristics, treatment, and survival from SystHERs","volume":"25","author":"Hurvitz","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022011714461606900_onco13965-bib-0039","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"2022011714461606900_onco13965-bib-0040","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022011714461606900_onco13965-bib-0041","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: Exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"key":"2022011714461606900_onco13965-bib-0042","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3171\/2013.3.JNS121900","article-title":"A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: Comparing treatment results for 1-4 vs \u2265\u20095 tumors: Clinical article","volume":"118","author":"Yamamoto","year":"2013","journal-title":"J Neurosurg"},{"key":"2022011714461606900_onco13965-bib-0043","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2018.0813","article-title":"Implications of screening for brain metastases in patients with breast cancer and non\u2013small cell lung cancer","volume":"4","author":"Cagney","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022011714461606900_onco13965-bib-0044","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11060-016-2264-0","article-title":"A case-matched study of stereotactic radiosurgery for patients with brain metastases: Comparing treatment results for those with versus without neurological symptoms","volume":"130","author":"Koiso","year":"2016","journal-title":"J Neurooncol"},{"key":"2022011714461606900_onco13965-bib-0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clbc.2017.12.009","article-title":"Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2-targeted therapy: An argument for earlier detection","volume":"18","author":"Morikawa","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"2022011714461606900_onco13965-bib-0046","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000440","article-title":"Risk factors for the development of brain metastases in patients with HER2-positive breast cancer","volume":"3","author":"Maurer","year":"2018","journal-title":"ESMO Open"},{"key":"2022011714461606900_onco13965-bib-0047","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.3390\/cancers12102787","article-title":"Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases","volume":"12","author":"Laakmann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2022011714461606900_onco13965-bib-0048","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-014-3090-8","article-title":"Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: A multicenter retrospective analysis","volume":"147","author":"Niikura","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2022011714461606900_onco13965-bib-0049","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cncr.28422","article-title":"Clinical and economic outcomes of patients with brain metastases based on symptoms: An argument for routine brain screening of those treated with upfront radiosurgery","volume":"120","author":"Lester","year":"2014","journal-title":"Cancer"},{"key":"2022011714461606900_onco13965-bib-0050","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.clbc.2019.06.007","article-title":"Incidence of brain metastases in nonmetastatic and metastatic breast cancer: Is there a role for screening?","volume":"20","author":"Komorowski","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"2022011714461606900_onco13965-bib-0051","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with HER2+ and triple negative metastatic breast cancer: A systematic review and meta-analysis","volume":"23","author":"Kuskis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2022011714461606900_onco13965-bib-0052","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3747\/co.27.5769","article-title":"A population-based analysis of breast cancer incidence and survival by subtype in Ontario women","volume":"27","author":"Seung","year":"2020","journal-title":"Curr Oncol"},{"key":"2022011714461606900_onco13965-bib-0053","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022011714461606900_onco13965-bib-0054","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.18632\/oncotarget.27238","article-title":"Central nervous system-specific efficacy of CDK4\/6 inhibitors in randomized controlled trials for metastatic breast cancer","volume":"10","author":"Nguyen","year":"2019","journal-title":"Oncotarget"},{"key":"2022011714461606900_onco13965-bib-0055","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1200\/JCO.2019.37.15_suppl.1017","article-title":"A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC)","volume":"37","author":"Anders","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022011714461606900_onco13965-bib-0056","doi-asserted-by":"crossref","first-page":"10784","DOI":"10.1038\/s41598-018-29062-w","article-title":"Buparlisib is a brain penetrable pan-PI3K inhibitor","volume":"8","author":"Gooijer","year":"2018","journal-title":"Sci Rep"},{"key":"2022011714461606900_onco13965-bib-0057","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/PO.19.00403","article-title":"Response of brain metastases from PIK3CA- mutant breast cancer to Alpelisib","volume":"4","author":"Batalini","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2022011714461606900_onco13965-bib-0058","first-page":"ii2","article-title":"Biom-07. Expression of androgen receptor and programmed death-ligand 1 in breast-to-brain metastases","volume":"22","author":"Qazi","year":"2020","journal-title":"Neurooncol"},{"key":"2022011714461606900_onco13965-bib-0059","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2022011714461606900_onco13965-bib-0060","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2022011714461606900_onco13965-bib-0061","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaoncol.2021.1359","article-title":"Central nervous system-specific outcomes of phase 3 randomized clinical trials in patients with advanced breast cancer, lung Cancer, and melanoma","volume":"70","author":"Corbett","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022011714461606900_onco13965-bib-0062","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022011714461606900_onco13965-bib-0063","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noz175.574","article-title":"Barriers to accrual and enrollment in brain tumor trials","volume":"21","author":"Lee","year":"2019","journal-title":"Neuro Oncol"},{"key":"2022011714461606900_onco13965-bib-0064","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2217\/fon-2020-0094","article-title":"Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases","volume":"16","author":"Zimmer","year":"2020","journal-title":"Future Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13965","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e1951\/42204033\/oncolo_26_11_e1951.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e1951\/42204033\/oncolo_26_11_e1951.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T14:48:32Z","timestamp":1642430912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/11\/e1951\/6508788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,9,21]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13965","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,9,21]]}}}